Compound 10b, at a high dose (20 mg/kg) given before TNBS administration, prevented the increase in TNF-α and PGE2 and, concomitantly, prevented the decrease in IL-10 colonic tissue levels in comparison to the colitis group (p < 0.05, p < 0.01, p < 0.01 vs. TNBS group, respectively, and p = NS vs. control group in all cases). Here, TNF is linked to colitis.